IMPACT OF THE PEGYLATED-INTERFERON AND RIBAVIRIN THERAPY ON THE TREATMENT-RELATED MORTALITY OF PATIENTS WITH CIRRHOSIS DUE TO HEPATITIS C VIRUS
AUTOR(ES)
DRESCH, Kelly Fernanda Nomura, MATTOS, Angelo Alves de, TOVO, Cristiane Valle, ONOFRIO, Fernanda Quadros de, CASAGRANDE, Leandro, FELTRIN, Alberi Adolfo, BARROS, Iago Christofoli de, ALMEIDA, Paulo Roberto Lerias de
FONTE
Rev. Inst. Med. trop. S. Paulo
DATA DE PUBLICAÇÃO
24/05/2016
RESUMO
Although the protease inhibitors have revolutionized the therapy of chronic hepatitis C (CHC), the concomitant use of pegylated-interferon (PEG-IFN) and ribavirin (RBV) is associated to a high rate of adverse effects. In this study, we evaluated the consequences of PEG-IFN and RBV and their relationship with mortality in patients with cirrhosis. METHODS: Medical records of CHC who underwent treatment with PEG-IFN and RBV in a public hospital in Brazil were evaluated. All the patients with cirrhosis were selected, and their clinical and laboratory characteristics, response to treatment, side effects and mortality were evaluated. RESULTS: From the 1,059 patients with CHC, 257 cirrhotic patients were evaluated. Of these, 45 (17.5%) achieved sustained viral response (SVR). Early discontinuation of therapy occurred in 105 (40.8%) patients, of which 39 (15.2%) were due to serious adverse effects. The mortality rate among the 257 cirrhotic patients was 4.3%, occurring in 06/242 (2.4%) of the Child-A, and in 05/15 (33.3%) of the Child-B patients. In conclusion, the treatment of patients with cirrhosis due to HCV with PEG-IFN and RBV shows a low SVR rate and a high mortality, especially in patients with liver dysfunction.
Documentos Relacionados
- Expectoration of large bronchial casts secondary to the treatment of chronic hepatitis c with pegylated interferon and ribavirin
- DEPRESSIVE EPISODE INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN
- Thyroid hormonal disturbances related to treatment of hepatitis C with interferon-alpha and ribavirin
- Splenectomy prior to antiviral therapy in patients with hepatitis C virus related decompensated cirrhosis
- Association of CYP3A4 genotype with treatment-related leukemia